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HER2 Targeted Molecular MR Imaging Using a De Novo
Designed Protein Contrast Agent
Jingjuan Qiao1, Shunyi Li1, Lixia Wei2, Jie Jiang1, Robert Long3, Hui Mao3, Ling Wei1, Liya Wang3,
Hua Yang4, Hans E. Grossniklaus4, Zhi-Ren Liu2*, Jenny J. Yang1*
1 Department of Chemistry, Georgia State University, Atlanta, Georgia, United States of America, 2 Department of Biology, Georgia State University, Atlanta, Georgia,
United States of America, 3 Department of Radiology, Emory University, Atlanta, Georgia, United States of America, 4 Department of Ophthalmology, Emory University
School of Medicine, Atlanta, Georgia, United States of America

Abstract
The application of magnetic resonance imaging (MRI) to non-invasively assess disease biomarkers has been hampered by
the lack of desired contrast agents with high relaxivity, targeting capability, and optimized pharmacokinetics. We have
developed a novel MR imaging probe targeting to HER2, a biomarker for various cancer types and a drug target for anticancer therapies. This multimodal HER20targeted MR imaging probe integrates a de novo designed protein contrast agent
with a high affinity HER2 affibody and a near IR fluorescent dye. Our probe can differentially monitor tumors with different
expression levels of HER2 in both human cell lines and xenograft mice models. In addition to its 100-fold higher dose
efficiency compared to clinically approved non-targeting contrast agent DTPA, our developed agent also exhibits
advantages in crossing the endothelial boundary, tissue distribution, and tumor tissue retention over reported contrast
agents as demonstrated by even distribution of the imaging probe across the entire tumor mass. This contrast agent will
provide a powerful tool for quantitative assessment of molecular markers, and improved resolution for diagnosis, prognosis
and drug discovery.
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prognoses with substantially higher probabilities of relapse after
treatment [8,9]. In addition, the HER2 mediated recognition
system has been widely employed as a drug target for anti-cancer
therapies. Unfortunately, current diagnosis of HER-2 positive
tumor relies mostly on the use of fine needle biopsies with
subsequent immunohistochemistry (IHC) analysis and/or fluorescent in situ hybridization (FISH). These methods suffer from
several drawbacks including sampling errors, misinterpretation
due to lack of quantization, and discordance between primary
tumors and metastases. Thus, assessment of HER2/neu levels by
non-invasive MR imaging will provide a tremendous tool for
cancer diagnosis/prognosis, design of treatment strategies, and
monitoring the effectiveness of the treatment.

Introduction
Molecular imaging specifically probes the molecular abnormalities of diseases to allow earlier detection, monitoring of disease
progression, and molecular assessment of treatments [1]. Molecular imaging using the modality of magnetic resonance imaging
(MRI) has significant advantages in pre-clinical research and
clinical diagnosis and prognosis as MRI offers superior spatial
resolution without depth limitation, exquisite soft tissue contrast,
clinical availability, while avoiding ionizing radiation [2]. However, many applications of MRI rely on the administration of
contrast agents to amplify the contrast of the interested regions to
obtain both sensitivity and specificity [3]. Developing contrast
agents that can be specifically targeted to various biomarkers
allowing real-time imaging of biological events at the molecular
level will have great clinical importance [4,5,6]. To achieve
molecular imaging by MRI, especially to quantitatively monitor
the expression level of the disease biomarkers, it is essential to
develop contrast agents with high relaxivity, target capability,
optimized pharmacokinetics, tissue penetration and low or no
toxicity [7].
Human epidermal growth factor receptor (EGFR) type 2
(HER2/neu) is a cell surface receptor of the EGF family that is
overexpressed in breast, ovarian, urinary bladder and many other
carcinomas. In the case of breast cancer, HER2 overexpression is
typically associated with younger patients and generally poor
PLoS ONE | www.plosone.org

Results
Metal binding affinity and relaxivity
We have developed a novel multimodal molecular imaging
probe to target cancer marker HER2/neu using magnetic
resonance and near infrared imaging (Fig. 1). We employed a
protein-based MRI contrast moiety (ProCA1) that was developed
by de novo designing the Gd3+ binding site(s) into a stable host
protein, the domain 1 of rat CD2 (10 KDa). Due to the unique
features of the designed metal binding properties, the protein
contrast agent exhibited a significant improved T1 relaxivity for
MRI contrast enhancement compared to that of commonly used
1
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Figure 1. Design and properties of multimodality HER2-targeted protein contrast agent ProCA1-affi for in vivo cancer targeting and
imaging by MRI and NIR. (A) The model structure of multimodal HER2 targeted MR imaging probe created by connecting a high affinity HER2
affibody ZHER2-342 at the C-terminal of a de novo designed protein contrast agent ProCA1.CD2 with a designed Gd3+ binding site. A near IR
fluorescence dye Cy5.5 was then conjugated to the added Cys at the C-terminal of the fusion protein. The designed probe was further modified by a
tri-branched polyethylene glycol (PEG) with 40 PEG subunits (ProCA1-affi-m). (B) The metal binding affinity for Gd3+ with Kd of 1.86610212 M was
measured by competitive method using Fluo5N [10] (C) The relaxivity of ProCA1-affi with (gray) and without PEGylation (ProCA1-affi-m, black) and
clinically used Gd-DTPA (white) were measured under the magnetic field of 1.41 T at 37uC (*P,0.05). The developed contrast agent exhibited 5–6 fold
greater relaxivity in both r1 and r2. *P is the value from Student’s t-test.
doi:10.1371/journal.pone.0018103.g001

excitation and emission maxima at 640 and 695 nm, respectively,
and excitation coefficient constant of 0.21 mM21cm21 (Supporting
File S1). Far UV CD and fluorescent spectra analyses indicated
that the developed contrast agent is well folded (Supporting File
S1). The toxicity of the designed protein was analyzed with CD-1
mice. No acute toxicity was observed following tail vein injections
of 4-fold greater dosages than that currently used in MRI,
evaluated over a 2-day test period. Characterization of serum
samples from the test mice receiving the agent detected no
apparent damage to kidney, liver, or heart (Supporting File S1).

Gd-DTPA (Diethylenetriamine Pentaacetic Acid) at 1.4–4.7T field
strength [10]. A high affinity HER2 affibody [11,12] was
engineered into the C terminal of the designed Gd3+-binding
protein by a flexible linker. The small molecular size (16 KDa)
provides good tissue penetration. We also introduced an optical
imaging capability by conjugating a near-IR dye Cy5.5 to a Cys
residue at C-terminal of the protein to facilitate imaging analyses
(Fig. 1A). To increase protein solubility, blood circulation time,
and reduction of immunogenicity, the designed HER2 targeting
protein contrast agent was PEGylated using PEG-40, a molecule
with tri-branches of 12 units PEG (denoted as ProCA1-affi-m,
Fig. 1A).
The designed MRI contrast agent was expressed in E. coli and
subsequently purified (Supporting File S1). Similar to the parental
protein ProCA1.CD2, the designed protein (ProCA1-affi) had a
strong metal binding affinity with Kd for Gd3+ at 1.87610–12 M
[10] (Fig. 1B). ProCA1-affi also exhibited r1 and r2 relaxivities of
21 and 30 mM21s21 at 1.41 T, respectively (Fig. 1B). The
developed protein with conjugated NIR dye exhibited fluorescence
PLoS ONE | www.plosone.org

Cancer cell targeting capability
We next examined whether the designed ProCA1-affi can target
to cancer cells by cell binding analyses. We used three human
cancer cell lines, AU565, SKOV-3 and MDA-MB-231. AU565 is
a human breast cancer cell line, with HER2 expression level
16106 HER2/cell. SKOV-3 is an ovarian cancer cell line with
estimated 36106 HER2/cell [13]. MBD-MDA-231 is a breast
cancer cell line with modest HER2 levels (,36104 HER2/cell)
2
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[14]. EMT-6 is a HER2 negative mouse breast cancer cell line.
Binding of the Gd-ProCA1-affi to the selected cells was first
analyzed by immuno-fluorescence staining using the polyclonal
antibody against PEGylated parental protein ProCA1
(PAbPGCA1) (Fig. 2). A substantial staining intensity of
ProCA1-affi bound to AU565 cells was observed and increased
as incubation times increased. In contrast, the EMT-6 cells
demonstrated very weak staining (Fig. 2A). It was evident that the
Gd3+ ProCA1-affi bound to the cell surface HER2 with a clear
membrane staining pattern in AU565 cells at 4uC (Fig. 2A).
However, binding of the Gd3+ proteins to the cells triggered
receptor mediated internalization at 37uC as demonstrated by the
staining of the intracellular ProCA1-affi. The majority of the
contrast agents entered the cells after 120 minutes incubation
(Fig. 2B). The Gd3+ ProCA1-affi was stable after internalization at
120 minutes, indicating that the designed Gd3+ ProCA1-affi
withstood protein degradation during and after endocytosis. The
immunostaining results were consistent with NIR fluorescence
imaging results (Supporting File S1). Binding of the Gd3+ ProCA1affi to the two testing cell lines were further analyzed by
quantification of cell bound Gd3+ by c-counting the trace of
isotope 153Gd3+- in the Gd3+ ProCA1-affi complexes (Fig. 2C).
The results supported our immuno-analyses that Gd3+ ProCA1affi was retained 3-4 folds greater in HER2 positive AU565 cells
than HER2 negative EMT-6 cells (Fig. 2). Measuring the amount
of bound Gd3+ from c-counting revealed that the Gd3+ ions were
bound to cells at ,0.1 fmole Gd/cell (P,0.01). Under assumption
that 16107 cells make a volume of 50–100 ml, this binding
capacity led to the accumulation of Gd3+ at 10–20 mM in the cell
pellets. This local concentration is sufficient to produce strong
MRI contrast, especially with the high relaxivity protein contrast
agent reported here.

Histology analysis of distribution and permeability
To further analyze the HER2 targeting properties of the protein
contrast agent, tumors and organs from the imaged mice were
collected 48 hours after administration of the agent (Fig. 3D). The
organs and tumors were imaged using optical animal imaging. It
was clear that there were very high levels of accumulation of Cy5.5
in the liver, kidneys, and the SKOV-3 tumor. There were medium
levels of the NIR dye at lung. In comparison, the level of Cy5.5 at
the MBD-MDA-231 tumor was quite low (Fig. 3D). The results
strongly suggested that our protein contrast agent led to the HER2
specific MR image enhancement.
To further verify the contrast agent targeted to the HER2
positive tumor, we carried out immunohistochemistry (IHC)
staining using the antibody PAbPGCA1 with tissue slides made
from the tumor samples collected from the imaged mice as well as
selected organs. The strongest staining was observed with liver and
the SKOV-3 tumor tissue slides (Fig. 4A). Close examination of
the staining patterns of the tumor slides revealed distribution of the
designed protein both inside and outside the cancer cells with
substantial stronger staining inside the cancer cells, indicating
internalization of the protein contrast agent. This staining pattern
provided a strong support for the cancer cell targeting by the
contrast agent. The kidney slides also gave strong immunostaining
consistent with the NIR imaging finding. Interestingly, the areas
near proximal tubes showed the strongest staining (Fig. 4A),
suggesting that the protein contrast agent may be secreted through
the kidney. This is consistent with observations that there were
good levels of both Gd3+ (by c-counting of 153Gd3+) and the
protein (by NIR fluorescence) in the urine of mice that were
injected with the contrast agent (data not shown). Immunostaining
of tissue sections from MBD-MDA-231 tumor revealed very weak
staining (Fig. 4A).
To further verify the HER2 specific MRI contrast enhancement, we carried out a competition assay based on the assumption
that if our protein contrast agent targeted HER2 and led to HER2
specific MRI contrast enhancement, affibody alone would be a
strong competitor for the binding to the cell surface HER2 and
consequently block the binding by our designed protein. Nude
mice that carried SKOV-3 tumors were pre-injected with buffer
saline or 3 mM of HER2 affibody ZHER2-342 labeled with Cy5.5
twice at 12 hr and 2 hr. Gd3+ ProCA1-affi-m (80 ml) at a
concentration of 3 mM was subsequently administrated to the
mice by intravenous injection. The mice were then scanned at a
4.7 T MRI scanner via the same procedures. Our results
demonstrated that the MRI contrast enhancements were not
observed at the SKOV-3 tumor site in the mice that received
HER2 affibody labeled with Cy5.5, while the contrast enhancements in the liver and kidney in the same mouse were not affected
by the administration of HER2 affibody (Supporting File S1). NIR
imaging did exhibit high intensity in the tumor, which indicates
that the affibody binds to the positive tumor and blocks the
binding of MRI contrast agents. Conversely, the administration of
the saline prior to injection of the designed protein contrast agent
did not block the MRI contrast enhancement (Supporting File S1).
The results with HER2 affibody blocking strongly support our
conclusion that the MRI contrast enhancement from administration of Gd3+ ProCA1-affi-m is HER2 specific.
A very crucial requirement for application of an agent for
delivery of both drugs and imaging probes to target a disease
marker is the capability of the agent to cross the endothelial barrier
and to allow for proper tissue penetration and distribution. In
particular, even distribution of an imaging probe throughout the
entire cancer site is vitally important for quantitative or semiquantitative assessment of a particular cancer marker. HER2 is

In vivo imaging on xenograft mice
We then tested whether our designed contrast agent would
result in MRI contrast enhancement in xenograft models of these
two human cancer cell lines. Due to less efficiency in formation of
xenograft tumors in nude mice using the AU565 cell line, and
extremely fast growth rate of the mouse breast cancer cell line
EMT-6 in xenograft, we switched to a very commonly used
ovarian cancer cell line SKOV-3 with a high HER2 expression
and a breast cancer cell line MDA-MB-231 with low expression
level of HER2. Xenograft models of these two cell lines had very
similar growth rates in nude mice. The SKOV-3 tumor cells were
subcutaneously implanted in the right flank, while the MBDMDA-231 with a low HER2 expression was implanted in the left
flank of the same mouse for direct comparison (Fig. 3A). The
contrast agent Gd3+ ProCA1-affi-m at concentration of 3 mM
(100 fold lower than clinically-approved contrast agent DTPA) was
administrated via the tail vein (80 ml of each mouse, n = 6). Preand post-contrast MRI were collected at different time points
using T1 and T2 weighted fast spin echo or T1 weighted gradient
echo sequences. At 3 hour time point, HER2 positive tumor
exhibited significant contrast enhancement. Strong contrast
enhancement was observed in the SKOV-3 tumor 24 hours after
injection, while there were much less changes in contrast in the
MBD-MDA-231 tumor (Fig. 3B, C). Such MRI contrast
enhancement was decreased after 24 hrs post injection. In parallel,
the mice were imaged using an optical animal imaging system
(Fig. 3A). Consistent with MR imaging, we observed a strong NIR
light emission from the SKOV-3 tumor at 24-hour postadministration of the contrast agent, however, the NIR intensities
at the MBD-MDA-231 tumor site were much less than that of the
SKOV-3 tumor (Fig. 3B).
PLoS ONE | www.plosone.org
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Figure 2. Examination of targeting capability in cultured cancer cells. (A) At 4uC, the HER2 positive (AU565) and negative (EMT-6) cancer
cells were treated with ProCA1- affi and ProCA1 -affi-m respectively for 2 hours. The HER2 expressed on the cell membrane of AU565 was revealed by
the green color from the goat-anti-rabbit secondary antibody (Invitrogen) for self-generated rabbit antibody against ProCA1-affi-m. The blue color
shows the nuclear staining. (B). At 37uC, the cancer cells with HER2 positive (AU565) and negative (EMT-6) were treated with ProCA1 -affi and ProCA1
-affi-m respectively for 5 min and 2 hours. The immunefluorescence staining studies revealed that ProCA1- affi and ProCA1- affi-m bind to HER2
positive cell extensively and were largely relocated into the cytosol via endocytosis after 2 hours (green color). The blue color shows the nuclear
staining. At both 4 and 37uC, negative staining was obtained in EMT-6 cells that lack HER2 expression. (C) (top) 153GdCl3, and153Gd loaded ProCA1 affi and ProCA1-affi-m were incubated with cultured cancer cells for 2 hours. After careful washing, the radioactive signaling in the cell pellets was
measured using c-counter. The retention of ProCA1-CD2-affi or ProCA1-CD2-affi-m with Gd3+ in HER2 positive cells (AU565) was ,3–4 folds greater
than that in the HER2 negative cells (EMT-6) and non-specific uptake in 153GdCl3 treated cells. (bottom) ELISA assay revealed that the specific binding
of HER2 positive cells by the developed contrast agents enhanced upon increasing the contrast agent concentrations.
doi:10.1371/journal.pone.0018103.g002
PLoS ONE | www.plosone.org
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Figure 3. In vivo cancer imaging of contrast agent uptake, retention and distribution in multiple different normal host organs and
in both SKOV-3 (HER2 positive, right) and MDA-MB-231 (HER2 negative, left) xenografts in balb/c nude mice (Charles River
laboratory). (A) NIR fluorescence imaging (Kodak 8000) revealed that ProCA1-Affi is able to target to the HER2 positive tumor (SKOV-3, right) 24 hr
after injection from tail vein. No significant near IR signal was detected in the HER2 negative tumor (MDA-MB-231, left) (n = 6, P,0.05). (B) Fast spin
echo and (C) gradient echo transversal MR images collected prior to injection and at various time points post injection of 3.0 mM of ProCA1-affi-m in
HEPES saline via tail vein. The MRI signal on the positive tumor (SKOV-3, right) exhibits significant enhancement at 3 hr post injection and reaches
maximum enhancement at 24 hours post injection (n = 6, P,0.05). The slight differences in MRI signals result from the use of different pulse
sequences for imaging (Methods). (D). NIR images of the dissected mouse organs. General bio-distribution was obtained based on the NIR signal and
western blot assay. The ProCA1-affi-m mainly distributed in the positive tumor, liver and kidney.
doi:10.1371/journal.pone.0018103.g003

PLoS ONE | www.plosone.org
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Figure 4. Histological examination of contrast agent uptake, retention and distribution in multiple different normal host organs
and in both SKOV-3 (HER2 positive, right) and MDA-MB-231 (HER2 negative, left) xenografts in balb/c nude mice (Charles River
laboratory) (n = 6, P,0.05). (A) Immune histology fluorescent (IHF) staining was applied to various tissue slides stained by antibody against
ProCA1-affi-m (red), Blood vessels biomarker CD31 (green), and nucleus DAPI (blue). The slides stained without primary antibody were used as blank
control. (B, C) The tissue penetration properties of ProCA1 –affi-m were compared with antibody by IHF staining. The tumor slides are from the mice
which were dissected 24 hr and 4 hr after injection with ProCA1-affi-m or antibody. After 4 hr, ProCA1 –affi-m began to distribute around the blood
vessel. The antibody had not been detected in the tumor tissue. After 24 hr, ProCA1-CD2-affi was evenly distributed in the tumor tissue and the
antibody mainly concentrated around the blood vessel. The scale bar value is 100 mm.
doi:10.1371/journal.pone.0018103.g004

evenly expressed across the entire SKOV-3 tumor as revealed by
immunostaining using a commercially available antibody (Sigma).
Co-staining using an antibody against the endothelial marker
PLoS ONE | www.plosone.org

CD31 revealed that the distribution of HER2 is not dependent on
the distance to the vessels (Supporting File S1). Presumably, the
proper size of ProCA1-affi-m provides a great advantage to target
6
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the molecular markers. To evaluate the tissue distribution and
endothelial penetration of our designed protein contrast agent, we
conducted immunofluorescence staining of the designed protein in
the tissue sections prepared from various organs after systematic
administration of the protein using the antibody PAbPGCA1. The
tissue sections were also co-stained with the antibody against
CD31. It was clear that high levels of ProCA1-affi-m were targeted
to the SKOV-3 tumor at 24 hours post injection, and the protein
was distributed in the entire tumor evenly since its intensity is not
changed significantly upon increasing the distance from vessel
staining CD31 to 40 mm (Fig. 4B). The results from the
immunofluorescence staining suggested that the designed protein
contrast agent had excellent endothelial and tumor tissue
penetration, and was not simply trapped in the blood in the
micro-vasculature of the tumor tissue.
Since antibodies have been widely used in drug and imaging
probe deliveries in molecular marker targeted applications [4,6]
we further compared the immunofluorescence staining patterns of
our designed protein agent and a commercially available HER2
antibody. To this end, ProCA1-affi-m (10 mg/kg) or the HER2
antibody (10 mg/kg) was administrated in the SKOV-3 tumor
bearing nude mice via tail vein. 24 hours post injection, tissue
sections were prepared from the tumor tissue, and the sections
were analyzed either by immunofluorescence staining using the
antibody PAbPGCA1 (for analyses of ProCA1-affi) or direct
application of the second antibody against rabbit IgG to detect the
bound anti-HER2 antibody. The tissue sections from both cases
were also co-stained with the antibody against CD31. At 24 hours
post injection, the anti-HER2 antibody was mainly concentrated
around endothelial cells as revealed by co-localization with antiCD31 staining. This is in sharp contrast to the even distribution of
ProCA1-affi-m in the entire tumor (Fig. 4B, C). The distributions
of the anti-HER2 antibody to the area distant from endothelial
cells were clearly quite reduced as demonstrated by weak
immunostaining in the areas where there was no CD31 staining
(Fig. 4B, C). We further examined the distribution of our protein
agent and the anti-HER2 antibody at an early time point. Tissue
sections from the SKOV-3 tumors were prepared 4 hours after
administration of ProCA1-affi-m or the anti-HER2 antibody.
Interestingly, while the ProCA1-affi-m was largely concentrated
with the CD31 staining in the tumor, the anti-HER2 antibody was
not detectable by the immunofluorescence staining analyses.
(Fig. 4C). The results strongly suggested that our designed protein
agent was able to cross the endothelial and distribute to the deep
tumor tissue a few hours after administration while the large size of
antibody (,160 kDa) significantly hindered endothelial and tissue
penetration. Consistent with the 50% reduction of MRI intensity
at the tumor site by affibody blocking shown in Supporting File S1,
the fluorescence immunostaining at the same tumor site also
exhibited about 60–90620% decrease in intensity (n = 6, P,0.05)
(Fig. 4C). Taken together, our developed MRI contrast agent
exhibits a potential capability for future quantitative analysis of the
biomarker in vivo.
HER2 has been validated as a very important prognosis and
treatment marker for cancer patients expressing HER2, especially
in the case of breast cancer. Development of Herceptin
(trastuzumab) and other HER2 targeting drugs has resulted in
significant improvement in patient survival. Unfortunately, current
methods for determination of HER2 status rely on invasive biopsy
coupled with IHC using a qualitative scoring system [15]. These
methods suffer from both high false positive and false negative
results, and large discordance in detection of HER2 expression in
primary tumors and metastases due to heterogeneity in tissue
sampling. These methods also cannot detect HER2 expression
PLoS ONE | www.plosone.org

levels and patterns in the entire cancer site. According to a recent
study by Philips et al., one in five HER2 clinical tests provided
incorrect results [16]. Therefore, there is a great need to develop
MRI contrast agents with specificity and sensitivity for HER2
imaging [17].

Discussion
In this present study, we demonstrate the success in molecular
imaging of HER2 by developing a novel class of multiple modality
contrast agent. To our knowledge, there is no previous report of
effective imaging of HER2 expression cancer in vivo by noninvasive
MRI with desirable tissue penetration and using only a single
injection. Our approach in designing protein-based molecular
imaging contrast agent differs greatly from previous reported studies
in several aspects and represents a significant advance in molecular
imaging by MRI. First, high relaxivity value in both T1 and T2
achieved by designing a Gd3+ binding site into a stable scaffold
protein [18] allows for increased sensitivity in the detection of disease
markers by MRI. Our achievement of MR imaging in animal with
100-fold lower dose usage than clinically used non-targeting agent
DTPA is also likely due to improved pharmokinetic properties such
as retention time and biodistribution. Such significant improvements
in in vivo dosage efficiency will potentially reduce potential Gd3+
toxicity risks, such as NSF (Nephrogenic Systemic Fibrosis). Second,
the relatively small molecular size of the designed agent provides a
unique opportunity to target the imaging probe to the molecular
marker in the entire tumor mass. This property is of vital
importance, especially for quantitative assessment of the molecular
marker based on the imaging results. Several approaches have been
employed to develop targeted MRI contrast agents [5,6,19,20,
21,22,23,24,25]. To increase contrast effects, high pay load contrast
molecules were created by either encapsulating a large number of
Gd-DTPA, conjugating multiple contrast agents such as polylysineGd-DTPA (PAMAM) [26], or using supermagnetic iron oxide
nanoparticles [27,28]. The antibody approach was widely utilized as
the targeting moiety either directly conjugated with high payload
contrast agent or elegantly applied in multiple steps to pre-label the
tumor as a biotin-labeled antibody [29]. These pioneering studies
demonstrated the feasibility of the targeting approach; however, the
large size of the antibody-conjugated imaging probes is likely to
severely limit the endothelial penetration and even-distribution of
the probes in the whole tumor (Fig. 4B and C). On the other hand,
our contrast agent exhibits endothelial penetration capabilities and
an excellent distribution in the entire cancer mass as revealed by its
adequate distribution near the blood vessel four hour after
administration, and the nearly-uniform distribution observed
24 hours post injection. One potential application of our developed
MRI contrast agent is for quantitatively or semi-quantitatively
assessing the HER2 levels in the entire tumor site using MR imaging,
which is impossible with any current methods. Since HER2 is
overexpressed in a large percentage of breast, ovarian, gastric,
urinary bladder and a number of other carcinomas, the developed
contrast agents may be beneficial for imaging of HER2 in several
types of cancer. In vivo real time monitoring of the changes in HER2
expression levels and patterns will provide vital information for
evaluation of the efficacy of drug treatments and for designing
further strategies for cancer treatments.

Materials and Methods
Ethics Statement
All the mice in this research were inoculated with human cancer
cell lines (SKOV-3 and MDA-MB-231) subcutaneously. All the
7
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contrast agents were injected from tail vein. The animal research
has been proved by IACUC (Institutional Animal Care and Use
Committee) of Georgia State University. The permit number of
our protocol is A06007. All the cancer cell lines used are
commercial available from ATCC.

0.066 s) and the T1 weighted gradient echo sequence
(TR = 0.088 s, TE = 2 s and P = 0.009 s). The fields of view are
3 cm63 cm with matrix of 2566256 and slice of 1 mm in
thickness. Image J was used to quantitatively analyze the MRI
images obtained. The regions of interest (ROI) were selected by
circling the tumor sites. Then the signal intensities of the ROIs
were calculated and compared. Six adjacent slides were selected to
measure signal changes which were averaged to obtain statistical
significant results.

Relaxivity and metal binding affinity measurement
Relaxation times, T1 and T2, were determined on the 1.41T
Minispec Relaxometer (mq60 NMR Analyzer, Bruker) at 37uC.
The ProCA1-affi and ProCA1-affi-m (modified by PEG) were
diluted with 10 mM Tris buffer, pH 7.0. Proteins prepared with a
series of concentrations: 40–120 mM, were applied for the
relaxation time measurement. The relaxivities, r1 and r2, were
obtained by fitting the relaxation times as a function of the Gd3+
concentrations (Fig. 1b). The Gd3+ -binding affinities with ProCA1affi and ProCA1-affi-m were investigated by the competitive assay
with the dye Fluo5N (a metal ion indicator, Invitrogen Molecular
Probes). The fluorescence spectra were collected on a fluorescence
spectrophotometer (Photon TechnologyInternational, Inc.) with a
10 mm path length quartz cell at room temperature [10].

Histology analysis
The mice were sacrificed after taking final images. Primary
organs, such as livers, kidneys, lungs, spleens, muscle and tumors
were dissected out for histology analysis. The tissues were frozen in
liquid nitrogen immediately following dissection. Then the frozen
tissues were sliced into mm thin sections. The sections were triple
stained with antibody against ProCA1-affi-m (red), CD31 antibody
(green) and DAPI (blue). Quantitative analysis on the tissue slides
was measured by the software Image J. Statistical results were
obtained from 2 tumor slides, and 3 view regions were taken from
each slide. Detection of the antibody decreased with increasing
distance from the blood vessel. The ProCA1Affi-m was found to
be well distributed throughout the whole tumor.

Tumor cell targeting
The AU565 (ATCC), originally from human breast cancer, has
an expression level of HER2 at about 106 per cell. The EMT6
(ATCC) is a HER2 negative cell line from mouse breast cancer.
The ProCA1-affi and ProCA1-affi-m were incubated with the two
kinds of cells at 4 and 37uC, respectively, for 1 hr. Then the cells
were washed 3 times, 5 min each with Tris buffer. The primary
antibody was generated on rabbit by using ProCA1-affi-m as
antigen. The secondary antibody was FITC conjugated (Invitrogen). Finally, the cells were mounted with Prolong antifade reagent
(Invitrogen). In the ELISA assay, the secondary antibody was
HRP conjugated and reacted with OPD for 5 min, and optical
density was measured at 490 nm. In the radioactive assay, the
ProCA1-affi binding with 153Gd3+ was used to treat the cancer
cells; the radioactivity of the cell pellets was measured by c counter
after washing 5 times.

Supporting Information
File S1 (A) Magnetic resonance images and image intensities of
the mouse tumor pre-blocked by affibody ZHER2:342 (B)
Purification of PEGylated ProCA1-affi-m (C) Far-UV CD and
Tryptophan fluorescent spectra (D) Optical spectrum of ProCA1affi-m conjugated with NIR dye Cy5.5 (E) NIR images of cultured
cancer cells (AU565 and SKOV-3) with high expression of HER2.
The scale bar value is 25 mm. (F) Immunofluorescent histology of
tumor tissue (Xenograft SKOV-3 model) stained by HER2
antibody and ProCA1-affi-m. The scale bar value is 100 mm.
(G) Blood circulation of GdCl3, ProCA1-affi and ProCA1-affi-m
in Xenograft nude mice (H) Toxicity analysis by clinical chemistry
assay.
(DOC)

Animal Model
The Balb/c nude mice were injected with ,26106 SKOV-3
(ATCC) and MDA-MB-231 (ATCC) cells (in 100 ml matrix gel
and saline mixture) subcutaneously on the right and left back
respectively. The xenografts were established during 4–6 weeks
until the tumor diameter reached approximately 5 to 10 mm.
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